The Facts on Gilead’s Greed:
· $6.5 billion in yearly revenues from AIDS drugs
· 36% profit margin – the highest in the industry
· $42 million in annual pay for CEO John Martin
· $10,600 annual price of Atripla for taxpayer-funded AIDS Drug Assistance Programs
· 8,300 people on waiting lists to receive lifesaving treatment
Given that Gilead produces these drugs “at cost” for a few hundred dollars per year, it can lower prices significantly and still make a huge profit, yet it has not.Today AIDS advocates are asking Gilead Sciences to do their part to end this AIDS drug crisis. Call Gilead and ask to speak with CEO John C. Martin - Gilead must immediately lower prices for ADAP. Thousands of lives are at risk.
Gilead